- Home
- MNR vs ANIP Comparison
MNR vs ANIP Comparison
Compare MNR & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNR | ANIP |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNR | ANIP |
|---|---|---|
| Price | $11.56 | $81.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $21.00 | ★ $102.14 |
| AVG Volume (30 Days) | 383.1K | ★ 417.1K |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | ★ 23.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.92 | ★ 1.67 |
| Revenue | ★ $956,307,000.00 | $826,880,000.00 |
| Revenue This Year | $21.87 | $43.41 |
| Revenue Next Year | $28.20 | $9.66 |
| P/E Ratio | ★ $12.74 | $48.00 |
| Revenue Growth | 9.45 | ★ 48.87 |
| 52 Week Low | $10.93 | $52.50 |
| 52 Week High | $19.00 | $99.50 |
Technical Indicators
Market Signals| Indicator | MNR | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 40.26 | 42.31 |
| Support Level | $12.27 | $79.98 |
| Resistance Level | $12.23 | $83.00 |
| Average True Range (ATR) | 0.33 | 2.27 |
| MACD | -0.02 | 0.23 |
| Stochastic Oscillator | 23.45 | 36.04 |
Price Performance
Historical ComparisonAbout MNR Mach Natural Resources LP
Mach Natural Resources LP is an independent upstream oil and gas company. The company is focused on the acquisition, development and production of oil, natural gas, and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas, and the panhandle of Texas.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.